Author:
Daniela Vinhas Bertolini,Luciana Scarlazzari Costa,Bruno Stuart de Castro,Tadeu Pernichelli,Inneke Marie van der Heijden,Silvia Figueiredo Costa,Helena Keiko Sato,Heloisa Helena de Sousa Marques
Publisher
Peertechz Publications Private Limited
Reference28 articles.
1. 1. Vipond C, Care R, Feavers IM (2012) History of meningococcal vaccines and their serological correlates of protection. Vaccine 30S: B10-B17. Link: http://bit.ly/31kBgHU
2. 2. Sikkema DJ, Friedman KE, Corsaro B, Kimura A, Hildreth SW, et al. (2000) Relationship between serum bactericidal activity and serogroupspecific immunoglobulin G concentration for adults, toddlers and infants immunized with Neisseria meningitidis serogroup C vaccines. Clin Diagn Lab Immunol 7: 764-768. Link: http://bit.ly/3b5WrC2
3. 3. Centers for Disease Control and Prevention (CDC) (2005) Morbidity and Mortality Weekly Report. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). May 27, 2005/54 (n. RR-7). Link: http://bit.ly/31kT0TD
4. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection;Borrow;Infect Immun 69 1568-1573 Link http//bit ly/36RFJ,2001
5. 5. Andrews N, Borrow R, Miller E (2003) Validation of serological correlate of protection for meningococcal conjugated vaccine by using efficacy estimates from post licensure surveillance in England. Clin Diagn Lab Immunol 10: 780-786. Link: http://bit.ly/36V8ZJc